We selected the following endogenously expressing PSMA and AR cells i) C4-2, a LNCaP subline, as it is PSA expressing androgen receptor (AR) mutant metastatic castration resistant prostate cancer (mCRPC) cell line that develops metastases in vivo21, 30); ii) C4-2B, which are C4-2 cells collected from bone metastases, potentially providing a different metastatic pattern than the parental C4-2 cells 21, 31-33); and iii) 22Rv1, which express PSA, are AR and Tp53 mutant, and represent both primary and relapsed PCa 34, 35. Here, AR is linked to posterior cortical atrophy.